Small intestinal bacterial overgrowth
diseaseOn this page
Also known as SIBO
Summary
Small intestinal bacterial overgrowth (MONDO:0400000) is a disease and 45 clinical trials. Top therapeutic interventions include rifaximin, metronidazole, and ciprofloxacin. A subtype of small intestine disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 45
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | small intestinal bacterial overgrowth |
| Mondo ID | MONDO:0400000 |
| UMLS | C3160854 |
| MedGen | 1708316 |
| Is cancer (heuristic) | no |
Also known as: SIBO
Disease family
Classification path: disease › human disease › disease by body system or component › digestive system disorder › intestinal disorder › small intestine disorder › small intestinal bacterial overgrowth
Related subtypes (9): small intestine diverticulitis, duodenal disorder, small intestine neoplasm, celiac disease, pouchitis, atresia of small intestine, congenital short bowel syndrome, enteritis, small intestine duplication
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 45.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 34 |
| PHASE4 | 3 |
| PHASE2/PHASE3 | 2 |
| EARLY_PHASE1 | 2 |
| PHASE1 | 2 |
| PHASE3 | 1 |
| PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02458781 | PHASE4 | UNKNOWN | Antibiotic Treatment Trial for Small Intestinal Bacterial Overgrowth |
| NCT03692299 | PHASE4 | COMPLETED | Effectiveness of Saccharomyces Boulardii for Gastrointestinal Bacterial-overgrowth in Systemic Sclerosis |
| NCT04841980 | PHASE4 | UNKNOWN | Rifaximin Therapy vs Low FODMAP Diet In IBS |
| NCT02470780 | PHASE2/PHASE3 | COMPLETED | Treating Bacterial Overgrowth in Parkinson’s Disease |
| NCT03318614 | PHASE2/PHASE3 | COMPLETED | Bifidobacterium Infantis M-63 Improves Mental Health in Irritable Bowel Syndrome Developed After a Major Flood Disaster |
| NCT04244877 | PHASE3 | WITHDRAWN | Rifaximin’s Effect on Covert Hepatic Encephalopathy With SIBO and Gastrointestinal Dysmotility |
| NCT04501380 | PHASE2 | UNKNOWN | Efficacy of AEMCOLO (Rifamycin SV MMX) in the Treatment of Small Intestinal Bacterial Overgrowth (SIBO) |
| NCT05967871 | PHASE1 | RECRUITING | Pilot Feasibility Study of Fecal Microbiota Transplant for the Treatment of Small Intestinal Bacterial Overgrowth |
| NCT06298409 | PHASE1 | RECRUITING | Evaluating the Effect Of Rifaximin on the Gut Microbiota and Metabolome in SIBO Using CapScan® |
| NCT03420976 | EARLY_PHASE1 | WITHDRAWN | Novel Supplement-based Therapy for the Treatment of Small Intestinal Bacterial Overgrowth |
| NCT04627727 | EARLY_PHASE1 | TERMINATED | Effect of a Low FODMAP Diet on SIBO Breath Test Positivity |
| NCT01822470 | Not specified | ENROLLING_BY_INVITATION | Small Intestinal Bacterial Overgrowth: A Prospective Registry |
| NCT04418258 | Not specified | RECRUITING | Capillary Endoscopy Aspiration Catheter |
| NCT04506593 | Not specified | RECRUITING | Indiana University Gastrointestinal Motility Diagnosis Registry |
| NCT06317441 | Not specified | RECRUITING | The Safety And Efficacy Of A Probiotic Intervention On Lactulose Hydrogen Breath Test-Positive Patients And Related Gastrointestinal Symptoms |
| NCT06483360 | Not specified | NOT_YET_RECRUITING | Methane and Hydrogen Breath Test for the Diagnosis of Small Intestinal Bacterial Overgrowth |
| NCT06772064 | Not specified | RECRUITING | Efficacy of Rifaximin in Patients With Small Intestinal Bacterial Overgrowth Presenting With Abdominal Bloating. |
| NCT07479238 | Not specified | NOT_YET_RECRUITING | Breath Test-Based Assessment of SIBO in Chronic Pancreatitis and Partial Pancreatectomy |
| NCT00619970 | Not specified | COMPLETED | Is Chronic Abdominal Pain in Pediatric Patients Due to Small Intestinal Bacterial Overgrowth? |
| NCT00680836 | Not specified | COMPLETED | Gulf War Digestive Health Study |
| NCT00956397 | Not specified | COMPLETED | Does Small Intestinal Bacterial Overgrowth Contribute to Functional Dyspepsia |
| NCT02251483 | Not specified | COMPLETED | Use of SBI in IBS Subjects Following a Successful Treatment of Small Intestinal Bacterial Overgrowth |
| NCT02439307 | Not specified | TERMINATED | Effycacy of Rifaximin on Reverse Minimal Hepatic Encephalopathy and Elimation Small Intestinal Bacterial |
| NCT02872961 | Not specified | COMPLETED | SIBO, Immune Activation, and FGIDs in Children |
| NCT03216239 | Not specified | COMPLETED | SIBO & SIFO After Colectomy |
| NCT03261856 | Not specified | COMPLETED | Clinical Utility of Breath Tests in GI |
| NCT03588845 | Not specified | UNKNOWN | The Small Intestine Bacterial Overgrowth Study Pilot |
| NCT03659175 | Not specified | UNKNOWN | Characteristic of Intestinal Flora in Male Elderly With Small Intestinal Bacterial Overgrowth |
| NCT04309396 | Not specified | COMPLETED | Clinical Utility of Handheld Hydrogen Breathalyzer in Identification of Food Sensitivities (AIRE Study) |
| NCT04316806 | Not specified | TERMINATED | Effect of a Probiotic Formula on Reducing SIBO in IBS Patients |
| NCT04492839 | Not specified | COMPLETED | Intestinal Adsorbent and Breath Gas Levels |
| NCT04499742 | Not specified | UNKNOWN | Comparative Assessment of Radioisotope Glucose and Breath Test |
| NCT04755673 | Not specified | COMPLETED | Atrantil for Intestinal Bacterial Overgrowth |
| NCT04867512 | Not specified | UNKNOWN | Botanical Blend on the Gut Microbiome and Gut-Skin-Axis in Small Intestinal Bacterial Overgrowth (SIBO) |
| NCT04910815 | Not specified | UNKNOWN | Feasibility of a New Diagnostic Device to Assess Small Intestinal Dysbiosis in Routine Clinical Setting. |
| NCT05122520 | Not specified | COMPLETED | Hydrogen and Methane Breath Test Questionnaire |
| NCT05579444 | Not specified | TERMINATED | Systems Biology of Gastrointestinal and Related Diseases |
| NCT05765994 | Not specified | COMPLETED | Small Intestinal Bacterial Overgrowth in Critically Ill Patients |
| NCT05915767 | Not specified | COMPLETED | Therapeutic Effect of Olive Leaf Tea on SIBO |
| NCT06162702 | Not specified | COMPLETED | Clinical Study of Fecal Microbiota Transplantation in the Treatment of Small Intestinal Bacterial Overgrowth (SIBO) |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| RIFAXIMIN | 4 | 3 |
| METRONIDAZOLE | 4 | 2 |
| CIPROFLOXACIN | 4 | 1 |
Related Atlas pages
- Drugs: Rifaximin, Metronidazole, Ciprofloxacin